Cargando…
No disparity of the efficacy and all‐cause mortality between Asian and non‐Asian type 2 diabetes patients with sodium–glucose cotransporter 2 inhibitors treatment: A meta‐analysis
AIMS/INTRODUCTION: To evaluate whether there is disparity of the efficacy and all‐cause mortality and other adverse effects between Asian and non‐Asian patients with sodium–glucose cotransporter 2 (SGLT2) inhibitors treatment. MATERIALS AND METHODS: Randomized clinical trials publicly available befo...
Autores principales: | Cai, Xiaoling, Gao, Xueying, Yang, Wenjia, Chen, Yifei, Zhang, Simin, Zhou, Lingli, Han, Xueyao, Ji, Linong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031489/ https://www.ncbi.nlm.nih.gov/pubmed/29029369 http://dx.doi.org/10.1111/jdi.12760 |
Ejemplares similares
-
Comparisons of weight changes between sodium‐glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment in type 2 diabetes patients: A meta‐analysis
por: Cai, Xiaoling, et al.
Publicado: (2017) -
Meta‐analysis and critical review on the efficacy and safety of alpha‐glucosidase inhibitors in Asian and non‐Asian populations
por: Gao, Xueying, et al.
Publicado: (2017) -
Update on the efficacy and safety of sodium–glucose cotransporter 2 inhibitors in Asians and non‐Asians
por: Fujita, Yoshihito, et al.
Publicado: (2019) -
Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023) -
Disparities in efficacy and safety of sodium-glucose cotransporter 2 inhibitor among patients with different extents of renal dysfunction: A systematic review and meta-analysis of randomized controlled trials
por: Hu, Suiyuan, et al.
Publicado: (2022)